Adding insult to injury! The core subsidiary of Shandong Sinobioway Biomedicine has been halted from production, with a revenue share of 60% | Quick read announcement.

① A subsidiary of Shandong Sinobioway Biomedicine responsible for the production and sale of interferon products has been subjected to risk control measures that involve the suspension of production and sales due to failing the Pharmaceutical GMP compliance inspection. ② Previously, Shandong Sinobioway Biomedicine's interferon α2b spray was recalled from shelves due to inspection results indicating that its "biological activity does not meet regulations."

cls.cn33minutes ago

The impact of U.S. tariff policy on the company is relatively small. Daan Gene Co.,Ltd.: There is currently no plan for shareholding increase | Spotlight on Earnings Conference.

① During the Earnings Conference, Daan Gene Co.,Ltd. General Manager Huang Luo stated that the current diagnostic reagent industry is experiencing both an expansion in market size and intensified market competition. ② The company indicated that since overseas revenue accounts for a small proportion, the USA's tariff increases have a limited impact on the company, but there are currently no plans for Shareholding.

cls.cnApr 10 08:32 ET

Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.

In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.

cls.cnApr 6 20:17 ET

The entire pharmaceutical sector has surged sharply; what happened?

On Monday, all AH Stocks in the pharmaceutical Sector surged, with innovative drugs performing the strongest. The Yinhua CSI Innovative Drugs Industry ETF collectively rose sharply, driven by three main factors: the relaxation of collective procurement, overseas license authorizations, and improvement in Earnings Reports that will reshape the Industry landscape.

wallstreetcnApr 1 08:38 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

Jiangsu Lianhuan Pharmaceutical: After nearly 0.3 billion failed placement, plans to borrow 0.2 billion from Banks for Innovative Drugs project "waiting for rice to cook" | Quick read announcement.

① Following the termination of the fundraising plan through the issuance of Convertible Bonds last year, Jiangsu Lianhuan Pharmaceutical has announced the termination of the plan to raise funds by issuing Stocks to specific targets through a simplified procedure. ② In order to develop Innovative Drugs projects, Jiangsu Lianhuan Pharmaceutical intends to apply for a research and development loan from the Jiangsu branch of the National Development Bank, with a credit amount of 0.24 billion yuan.

cls.cnFeb 24 09:38 ET